BioPharma Dive February 16, 2024
The FDA issued a partial hold on four tests of magrolimab in solid tumors, as Gilead evaluates the program’s future.
Gilead Sciences is evaluating the future of a cancer drug acquired in a multibillion-dollar deal following a new setback the company reported late Thursday.
In a statement, Gilead said it paused enrollment in four mid-stage trials of the drug, known as magrolimab, in different types of solid tumors. The Food and Drug Administration subsequently ordered a partial hold on these trials. The suspension also applies to investigator-run tests of magrolimab, the company said.
Gilead didn’t specify why it stopped recruiting study participants. However, one week ago, the company disclosed a regimen involving magrolimab was associated with an increased risk of...
Today's Sponsors
Today's Sponsor